083790.KQ
CG Invites Co., Ltd.
KOE · Healthcare · Biotechnology · KR
KRW 843.00
+0.12%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 27.0B | 27.4B | 7.3B | 4.9B | 4.3B |
| Cost of Revenue | 36.9B | 34.0B | 7.8B | 3.4B | 3.1B |
| Gross Profit | (9.8B) | (6.6B) | (519.1M) | 1.5B | 1.3B |
| Operating Expenses | |||||
| R&D Expense | 4.1B | 4.4B | 11.3B | 7.2B | 6.3B |
| SG&A Expense | 5.3B | 5.4B | 14.6B | 16.4B | 12.9B |
| General & Admin Expense | 173.5M | 1.6B | 1.8B | 1.9B | 1.2B |
| Selling & Marketing Expense | 1.8B | 3.8B | 12.8B | 14.5B | 11.7B |
| Other Expenses | 2.8B | 7.2B | 12.4B | 8.8B | 5.1B |
| Total Operating Expenses | 12.7B | 17.0B | 38.3B | 32.4B | 24.3B |
| Cost and Expenses | 49.5B | 51.0B | 46.1B | 35.8B | 27.4B |
| Operating Income (EBIT) | (22.5B) | (23.7B) | (38.8B) | (30.9B) | (23.0B) |
| Non-Operating | |||||
| Interest Income | 612.8M | 944.6M | 1.2B | 2.4B | 1.8B |
| Interest Expense | 4.1B | 4.3B | 3.5B | 2.1B | 1.1B |
| Net Interest Income | (3.5B) | (3.3B) | (2.3B) | 326.3M | 732.1M |
| Other Non-Op Income/Expense | 5.9B | 3.2B | (11.2B) | (20.2B) | 303.7M |
| Non-Operating Income (excl Interest) | (10.8B) | — | 7.8B | 18.1B | (1.4B) |
| EBT (Pre-Tax Income) | (16.6B) | (20.4B) | (50.1B) | (51.2B) | (22.7B) |
| Income Tax Expense | (7.9B) | (7.9B) | 1.7B | (2.9B) | 614.6M |
| Bottom Line | |||||
| Net Income | 428.9M | (3.5B) | (51.5B) | (48.9B) | (23.9B) |
| Earnings from Cont. Ops | (8.7B) | (12.5B) | (51.8B) | (48.2B) | (23.4B) |
| Earnings from Discont. Ops | (56.6M) | — | — | (1.8B) | (2.2B) |
| Bottom Line Net Income | 428.9M | (3.5B) | (51.5B) | (48.9B) | (23.9B) |
| Per Share | |||||
| Basic EPS | ₩4 | (₩46) | (₩669) | (₩661) | (₩345) |
| Diluted EPS | ₩4 | (₩46) | (₩669) | (₩661) | (₩345) |
| Revenue Per Share | ₩352 | ₩356 | ₩94 | ₩66 | ₩62 |
| Shares | |||||
| Basic Shares Outstanding | 76.8M | 76.9M | 76.8M | 74.0M | 69.2M |
| Diluted Shares Outstanding | 76.8M | 76.9M | 76.8M | 74.0M | 69.2M |
| Profitability Metrics | |||||
| EBITDA | (21.2B) | (17.0B) | (42.3B) | (28.9B) | (18.2B) |
| D&A | 6.7B | 6.6B | 4.3B | 3.2B | 3.5B |
| EBIT | (27.9B) | (23.7B) | (46.6B) | (32.1B) | (21.7B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026